Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the third quarter ended September 30, 2008.

"We continue to make rapid progress in both of our hepatitis C development programs," said Steve Worland Ph.D., President and CEO of Anadys. "We completed our first clinical study of ANA598 in healthy volunteers and have now completed the healthy volunteer portion of our ongoing ANA773 study. For both programs, we are very encouraged by the data and look forward to initiating patient dosing this quarter."

Financial Results

As of September 30, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $34.4 million.

During the third quarter of 2008 the Company had no revenue, compared to $21.5 million for the same quarter of 2007. The revenue in the third quarter of 2007 was primarily derived from the recognition of previously deferred revenue associated with an upfront payment and a milestone payment under a prior collaboration.

Research and development expenses were $7.6 million for the third quarter of 2008 and 2007. During the third quarter of 2008, cost savings derived from Anadys' completed strategic restructuring and associated termination of prior development programs were offset by a significant increase in ANA598 development costs.

General and administrative expenses were $2.1 million for the third quarter of 2008, compared to $2.4 million for the third quarter of 2007. The $0.3 million decrease primarily resulted from cost savi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... LAUDERDALE, Fla. , Feb. 26, 2015 ... discussed growth priorities driven by key research advancements and ... segments at today,s Bank of America Merrill Lynch 2015 ... met the challenge of building grain supplies the last ... to continue at the pace of the last decade, ...
(Date:2/26/2015)... Feb. 26, 2015 The healthcare landscape is rapidly ... Frost & Sullivan will host its 20 th ... , March 8 to 10, at the Hilton San Diego ... This event is a platform for global ... discuss industry disruptions and how to succeed in an uncertain ...
(Date:2/26/2015)... Innovation is more urgent than ... parts of the world and transforming global markets ... manufacturing to health care, disruption is constantly underway. ... socio-political trends shake the foundations of established business ... CEOs to survive the next wave of mega-change. ...
(Date:2/26/2015)... February 26, 2015 Regis Technologies ... development of oncology drug substances. , Regis Technologies is ... their new Potent Compound Suite (PCS) for 2015. , ... square foot, cGMP facility in Morton Grove, Illinois. The ... of potent compounds up to about one kilogram per ...
Breaking Biology Technology:DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Regis Extends cGMP Services to Oncology Market 2
... at 7:00 p.m. Eastern Time in Conjunction with ... Leading Cardiothoracic Surgeons Conference - ... (Nasdaq: CRDC ) and Intuitive,Surgical, Inc. (Nasdaq: ISRG ... topic of "Advanced Techniques and Technologies in Robotic,Coronary Revascularization and ...
... 18 ,ThromboGenics NV (Euronext Brussels: THR) and ... announce today that they,have received approval from ... Phase I clinical trial of the novel ... that targets the angiogenic factor PlGF,(placental growth ...
... Jan. 17, 2008 Scientific studies on climate change, ... awarded more than 145 million processing hours on supercomputers ... Energys Innovative and Novel Computational Impact on Theory and ... from industry, academia and government research facilities receive access ...
Cached Biology Technology:Cardica and Intuitive Surgical to Host Educational Symposium on 'Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair' 2Cardica and Intuitive Surgical to Host Educational Symposium on 'Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair' 3Cardica and Intuitive Surgical to Host Educational Symposium on 'Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair' 4Cardica and Intuitive Surgical to Host Educational Symposium on 'Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair' 5ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 2ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 3ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 4ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 5Oak Ridge leads DOE INCITE effort in 2008 2Oak Ridge leads DOE INCITE effort in 2008 3Oak Ridge leads DOE INCITE effort in 2008 4
(Date:1/22/2015)... Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of ... of its new website design. "When we launched ... says Peter O,Neill , founder and CEO of FindBiometrics. ... needs involvement from the key players on a very broad ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a leader ... announced the launch of a TR-FRET (time resolved ... Transcreener UDP Assay, a high throughput screening assay ... assay will allow for sensitive detection of hundreds ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... NY (May 14, 2012) -- Dr. Darja Marolt, an Investigator ... lead author on a study showing that human embryonic stem ... use in research and potential therapeutic application. Dr. Marolt conducted ... Columbia University in the laboratory of Dr. Gordana Vunjak-Novakovic. ...
... May 14, 2012 Scientists from the Florida campus of ... grant from the National Institute on Drug Abuse of the ... help prevent relapse in smokers who are kicking the habit. ... grant, which is designed to support an institutionally based research ...
... data enables students to carry out scientifically valid virtual ... is created and developed, according to research from the ... of Gothenburg followed upper-secondary students from the Swedish town ... of the research project I2I, Inquiry to Insight., Using ...
Cached Biology News:Scripps Florida scientists awarded $8.4 million grant to develop new anti-smoking treatments 2Real science in virtual school labs 2
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Applications: Western blotting Stability: Room temperature, indefinitely ...
... Rabbit Antibody to ARG. Vasopressin ... arginine vasopression peptide. Cells are found ... and fibers are found throughout the ... FA perfused tissue. ...
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Biology Products: